长期马拉维若治疗对HIV阳性患者非AIDS相关合并症的影响
马拉维若组非AIDS定义疾病发生率低于非马拉维若组,但未达到统计学显著性;甘油三酯仅在马拉维若组下降。
要点
- 马拉维若组非AIDS定义疾病发生率较低,但差异未达统计学显著。
- 甘油三酯仅在马拉维若组下降,其余炎症和免疫学参数两组均无显著变化。
- 仅在非马拉维若组观察到hsCRP与血脂的正相关,马拉维若组未发现。
核心结论
- 数据提示马拉维若在感染病程较长人群中可能对非AIDS相关合并症的发生具有保护作用,并可能调节脂质依赖性炎症。
主要发现
- 马拉维若组基线时HIV感染时间更长、合并症患病率更高、多重用药更频繁。
- 马拉维若组非AIDS定义疾病发生率低于非马拉维若组,但未达到统计学显著性。
- 除甘油三酯仅在马拉维若组下降外,两组炎症和免疫学参数在研究结束时均无显著变化。
- T3时两组hsCRP与高密度脂蛋白均呈负相关(马拉维若Spearman rho -0.30,P=0.05;非马拉维若-0.23,P=0.0003)。
- 仅在非马拉维若组观察到hsCRP与血脂的正相关:T0时hsCRP/LDL +0.17(P=0.004)、hsCRP/总胆固醇+0.20(P=0.0007)、hsCRP/甘油三酯+0.12(P=0.04),T3时hsCRP/LDL +0.26(P<0.0001)、hsCRP/总胆固醇+0.24(P=0.0001)、hsCRP/甘油三酯+0.15(P=0.02),马拉维若组未发现这些相关性。
临床怎么用
- 对感染病程较长、合并症负担较重的HIV患者,马拉维若可能有助于降低非AIDS相关合并症风险并调节脂质相关炎症,但需结合个体情况评估。
- 治疗中可关注甘油三酯变化及hsCRP与血脂、D-二聚体的相关性,作为炎症和血栓风险监测的参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This retrospective study evaluates the effect of maraviroc, the first CCR5 receptor antagonist, on non-AIDS-related comorbidity incidence and its impact on inflammatory and lipid parameters. METHODS: Seventy-four HIV patients on maraviroc treatment were compared with 312 patients never exposed to maraviroc (matched for sex, age and CD4 nadir). RESULTS: At baseline (T0), maraviroc patients presented a longer duration of HIV infection, a higher prevalence of comorbidities and a greater frequency of polypharmacy. Non-AIDS-defining disease incidence was lower in the maraviroc group than in the non-maraviroc group (without achieving statistical significance). Except triglycerides (TGL), which dropped only in the maraviroc group, inflammatory and immunological parameters did not significantly change in either group by the end of the study period (T3). At T3, high-sensitivity C-reactive protein (hsCRP) and high-density lipoprotein were inversely correlated in both groups (Spearman's rho: maraviroc -0.30, P = 0.05; non-maraviroc -0.23, P = 0.0003). Only in the non-maraviroc group was the positive correlation between hsCRP and lipids observed both at T0 (hsCRP/low-density lipoprotein (LDL) +0.17, P = 0.004; hsCRP/total cholesterol +0.20, P = 0.0007; hsCRP/TGL +0.12, P = 0.04) and T3 (hsCRP/LDL +0.26, P < 0.0001; hsCRP/total cholesterol +0.24, P = 0.0001; hsCRP/TGL +0.15, P = 0.02). These correlations were not found in the maraviroc group. A significant positive correlation was found at T0 and at T3 between hsCRP and D-dimer in both groups (maraviroc: T0 +0.46, P = 0.0007; T3 +0.41, P = 0.006; non-maraviroc: T0 +0.17, P = 0.02; T3: +0.17, P = 0.017). CONCLUSIONS: These data suggest a possible protective role of maraviroc in the incidence of non-AIDS-related comorbidities in a population with longer-lasting infection and allow us to hypothesize its role in the modulation of lipid-dependent inflammation.
引用
- Piconi S, Foschi A, Malagoli A, et al. Impact of prolonged maraviroc treatment on non-AIDS-related comorbidities in HIV-positive patients: a retrospective cohort study. J Antimicrob Chemother. 2019. PMID: 31139818. doi:10.1093/jac/dkz227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。